|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,514 GBX | -0.39% |
|
-2.39% | +27.76% |
| Apr. 03 | Craig-Hallum Starts Indivior With Buy Rating, $37 Price Target | MT |
| Mar. 27 | C4X Discovery seeks AIM delisting but half-year revenue skyrockets | AN |
British drugmaker Indivior said on Monday it had appointed Mark Crossley as chief executive to replace Shaun Thaxter, who had stepped down in mutual agreement with the board.
Crossley has been chief financial officer of the group, which makes medicines to treat addiction, since 2017, Indivior said, and as chief strategy officer from 2014-2017 helped lead the demerger of the company from Reckitt Benckiser.
(Reporting by Paul Sandle; editing by Kate Holton)
| 1st Jan change | Capi. | |
|---|---|---|
| +27.76% | 2.56B | |
| +5.73% | 71.48B | |
| +11.94% | 9.18B | |
| -15.34% | 4.79B | |
| +34.54% | 3.98B | |
| +5.09% | 3.97B | |
| -28.33% | 2.29B | |
| -24.15% | 2.23B | |
| +6.23% | 1.92B | |
| -0.50% | 1.64B |
INDIVIOR PLC 
